Skip to main content

Table 1 Patient demographic and disease characteristics

From: Dose-intense capecitabine, oxaliplatin and bevacizumab as first line treatment for metastatic, unresectable colorectal cancer: a multi-centre phase II study

  Total C1750 mg/m2 C1500 mg/m2
  n = 49 n = 19 n = 30
Age at registration, median (IQ range) 63 (55, 67) 64 (52, 68) 62 (55, 65)
Gender, n (%)    
Female 31 (63.3) 11 (57.9) 20 (66.7)
Male 18 (36.7) 8 (42.1) 10 (33.3)
Ethnicity, n (%)    
European 47 (96.0) 18 (94.7) 29 (96.7)
Maori 1 (2.0) 1 (5.3) 0 (0.0)
Other 1 (2.0) 0 (0.0) 1 (3.3)
Histology, n (%)    
Adenocarcinoma - NOS 20 (40.8) 7 (36.8) 13 (43.3)
Adenocarcinoma - poorly differentiated 4 (8.2) 2 (10.5) 2 (6.7)
Adenocarcinoma - moderately differentiated 17 (34.7) 9 (47.4) 8 (26.7)
Adenocarcinoma - well differentiated 1 (2.0) 1 (5.3) 0 (0.0)
Mucinious 7 (14.3) 0 (0.0) 7 (23.3)
Disease Status, n (%)    
Distant metastases only 41 (83.7) 17 (89.5) 24 (80.0)
Local recurrence 5 (10.2) 2 (10.5) 3 (10.0)
Distant metastases and local recurrence 3 (6.1) 0 (0.0) 3 (10.0)
Prior Anticancer Treatment, n (%)    
Prior Adjuvant Chemotherapy 11 (22.4) 5 (26.3) 6 (20.0)
Radiotherapy 8 (16.3) 3 (15.8) 5 (16.7)
Surgery 44 (89.8) 17 (89.5) 27 (90.0)
WHO Performance Status, n (%)    
0 42 (85.7) 18 (94.7) 24 (80.0)
1 7 (14.3) 1 (5.3) 6 (20.0)
\